Read by QxMD icon Read

Thrombosis Research

Kazuhiro Nagata, Shinpei Arai, Chiaki Taira, Mitsutoshi Sugano, Takayuki Honda, Nobuo Okumura
No abstract text is available yet for this article.
October 2, 2017: Thrombosis Research
Joanna Sikora, Krzysztof Pstrągowski, Natalia Skibińska, Przemysław Sobczak, Adam Sikora, Michał Piotr Marszałł, Tomasz Fabiszak, Grzegorz Grześk, Jacek Kubica
Levosimendan has been developed for treatment of severe heart failure. The favorable hemodynamic effect of levosimendan is related to its unique dual mechanism of action - increase of the contractile force of the myocardium caused by enhanced sensitivity of myofilaments to calcium combined with vasodilatation caused by the opening of adenosine triphosphate - dependent potassium channels. Due to the structural similarities to phosphodiesterase inhibitors it may partly exert its action via inhibition of phosphodiesterase inhibitors III...
October 2, 2017: Thrombosis Research
Philippe Robin, Pierre-Yves Le Roux, Cécile Tromeur, Benjamin Planquette, Nathalie Prévot-Bitot, Christian Lavigne, Jean Pastre, Adel Merah, Francis Couturaud, Grégoire Le Gal, Pierre-Yves Salaun
Venous thromboembolism (VTE) can occur as the first manifestation of an underlying occult malignancy. It remains unclear whether or not a better selection of high risk patients might lead to more efficient occult cancer screening strategies. Our aim was to assess the predictors of occult malignancy diagnosis in patients with unprovoked VTE. Univariate analyses were performed to assess the effect of candidate predictors on occult cancer detection in patients enrolled in a prospective, multicenter, randomized, controlled study (MVTEP study) whose primary aim was to compare a limited screening strategy with a strategy combining limited screening and FDG PET/CT in patients with unprovoked VTE...
September 28, 2017: Thrombosis Research
Leslie Skeith, Carol Gonsalves
Practice variation, the differences in clinical management between physicians, is one reason why patient outcomes may differ. Identifying factors that contribute to practice variation in areas of clinical uncertainty or equipoise may have implications for understanding and improving patient care. To discern what factors may influence practice variation, we completed a qualitative content analysis of all practice-pattern surveys in thrombosis medicine in the last 10years. Out of 2117 articles screened using a systematic search strategy, 33 practice-pattern surveys met eligibility criteria...
September 27, 2017: Thrombosis Research
Annika de Jong, Jeroen Eikenboom
Von Willebrand disease (VWD) is a bleeding disorder that is mainly caused by mutations in the multimeric protein von Willebrand factor (VWF). These mutations may lead to deficiencies in plasma VWF or dysfunctional VWF. VWF is a heterogeneous protein and over the past three decades, hundreds of VWF mutations have been identified. In this review we have organized all reported mutations, spanning a timeline from the late eighties until early 2017. This resulted in an overview of 750 unique mutations that are divided over the VWD types 1, 2A, 2B, 2M, 2N and 3...
September 23, 2017: Thrombosis Research
Elisabeth Pasquier
No abstract text is available yet for this article.
September 23, 2017: Thrombosis Research
Line Hjellström, Ashkan Labaf
BACKGROUND: Mechanical heart valve (MHV) patients undergoing invasive procedures necessitating an interruption of their lifelong anticoagulant therapy, often require bridging with low-molecular weight heparin (LMWH) or unfractionated heparin. The aim of this study was to assess whether bridging MHV patients with prophylactic doses of LMWH undergoing invasive, elective procedures is a safe and effective method. METHOD: This observational cohort study included all MHV patients on vitamin K anticoagulant therapy in Malmö, registered and monitored via AuriculA (the Swedish national quality registry for atrial fibrillation and anticoagulation), between 1/1/2008 and 31/12/2011...
September 23, 2017: Thrombosis Research
Anping Dong, Paul Mueller, Fanmuyi Yang, Liping Yang, Andrew Morris, Susan S Smyth
INTRODUCTION: The multifunctional serine protease thrombin exerts proinflammatory and profibrotic cellular effects that may contribute to cardiac remodeling. This study was designed to investigate whether direct thrombin inhibition with dabigatran attenuates myocardial injury in the setting of pressure overload-induced heart failure. MATERIAL AND METHODS: Transverse aortic constriction (TAC) surgery was performed on C57Bl/6J male mice to elicit cardiac hypertrophy...
September 21, 2017: Thrombosis Research
Lydia A Haile, Roshni Rao, Swamy K Polumuri, Gowthami M Arepally, David A Keire, Daniela Verthelyi, Cynthia D Sommers
INTRODUCTION: Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication of heparin anticoagulation therapy resulting in thrombocytopenia frequently accompanied by thrombosis. Current evidence suggests that HIT is associated with antibodies developed in response to multi-molecular complexes formed by platelet factor 4 (PF4) bound to heparin or cell surface glycosaminoglycans. These antibody complexes activate platelets and monocytes typically through FcγRIIA receptors increasing the production of PF4, inflammatory mediators, tissue factor and thrombin...
September 21, 2017: Thrombosis Research
Fausto G Gomes, Vanessa Sandim, Vitor H Almeida, Araci M R Rondon, Barbara B Succar, Eugenio D Hottz, Ana Carolina Leal, Brunno Renato F Verçoza, Juliany Cola F Rodrigues, Patrícia T Bozza, Russolina B Zingali, Robson Q Monteiro
INTRODUCTION: Cancer-associated thrombosis is one of the major causes of worse prognosis among tumor-bearing patients. Extracellular vesicles derived from cancer cells, which can be divided mainly into microvesicles and exosomes, can participate in several tumor progression phenomena. Tumor-derived microvesicles positive for tissue factor (TF) have been associated with thrombotic risk in certain cancer types. Cancer cell-derived exosomes, however, have not. In this study we evaluated the capacity of extracellular vesicles (EVs, containing both microvesicles and exosomes) derived from breast-cancer cell lines in promoting platelet activation, aggregation and plasma coagulation, in experiments that access both TF-dependent and -independent activities...
September 21, 2017: Thrombosis Research
Shogo Tamura, Moe Murata-Kawakami, Yuki Takagi, Sachiko Suzuki, Akira Katsumi, Akira Takagi, Tetsuhito Kojima
INTRODUCTION: Antithrombin resistance (ATR) prothrombinemia is an inherited thrombophilic disorder caused by missense mutations in prothrombin gene (F2) at Arg596 of the sodium-binding region. Previously, prothrombin mutants Yukuhashi (Arg596Leu), Belgrade (Arg596Gln), and Padua 2 (Arg596Trp) were reported as ATR-prothrombins possessing a risk of familial venous thrombosis. To identify additional F2 mutations causing the ATR-phenotype, we investigated the coagulant properties of recombinant prothrombins mutated at amino acid residues within the sodium-binding region by single nucleotide substitutions (Thr540, Arg541, Glu592, and Lys599)...
September 20, 2017: Thrombosis Research
Ann Helen Kristoffersen, Eva Ajzner, Josep Miquel Bauça, Paolo Carraro, Ana Paula Faria, Andreas Hillarp, Dunja Rogic, Eser Y Sozmen, Joseph Watine, Piet Meijer, Sverre Sandberg
No abstract text is available yet for this article.
September 18, 2017: Thrombosis Research
Rick T Ikesaka, Susan R Kahn, Jean-Philippe Galanaud, Fernando J Vazquez, Graham Roche-Nagle, Marc Carrier, Gregoire Le Gal, Marc Rodger, Esteban Gandara
OBJECTIVES: The development of post thrombotic syndrome (PTS) is a major source of morbidity and reduced quality of life. We sought to determine the value assigned by clinicians to post thrombotic syndrome and whether clinicians believe that any post thrombotic syndrome or severe post thrombotic syndrome are important outcomes to assess after deep vein thrombosis (DVT) as compared to other outcomes. DESIGN: The design of the study was a self-responded electronic survey...
September 15, 2017: Thrombosis Research
Yan Chen, Jian-Xin Li, Ying Song, Jing-Jing Xu, Xiao-Fang Tang, Lin Jiang, Ping Jiang, Ru Liu, Huan-Huan Wang, Xue-Yan Zhao, Jue Chen, Zhan Gao, Shu-Bin Qiao, Run-Lin Gao, Yue-Jin Yang, Bo Xu, Jin-Qing Yuan
INTRODUCTION: Stent thrombosis (ST) is a rare but catastrophic complication of percutaneous coronary intervention, leading to poor prognosis. Endothelin-1 (ET-1) plays an important role in endothelial dysfunction and thrombogenesis. However, the impact of big ET-1 level on ST in patients with coronary stenting is unknown. We aimed to evaluate big ET-1 level as a potential predictor of ST in patients undergoing percutaneous coronary intervention. MATERIALS AND METHODS: From January 2013 to December 2013, 8106 consecutive patients underwent successful coronary stent implantation and were prospectively enrolled in this study...
September 13, 2017: Thrombosis Research
Paula X Arata, Valeria Genoud, Ana Maria Lauricella, Marina Ciancia, Irene Quintana
No abstract text is available yet for this article.
September 13, 2017: Thrombosis Research
E G Bouck, E R Zunica, M T Nieman
No abstract text is available yet for this article.
September 12, 2017: Thrombosis Research
Aileen Kharat, Anne-Lise Hachulla, Stéphane Noble, Frédéric Lador
Chronic thromboembolic pulmonary hypertension (CTEPH) should be suspected in patients presenting persistent dyspnea three months after a pulmonary embolism or in patients presenting with acute pulmonary embolism and suggestive images on the CT-scan. For these patients, a specific diagnostic work-up should be performed. First step consists of the ventilation/perfusion (V/Q) scan which is a good screening test due to its high sensitivity and high negative predictive value. Pulmonary angiography remains the gold standard approach for the confirmation of the diagnosis and pre-surgical evaluation of CTEPH...
September 9, 2017: Thrombosis Research
Mariasanta Napolitano, Sergio Siragusa
No abstract text is available yet for this article.
September 8, 2017: Thrombosis Research
Paul R J Ames, José Delgado Alves, Fabrizio Gentile
No abstract text is available yet for this article.
September 8, 2017: Thrombosis Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"